The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse aficamten (Myqorzo®) from the basic health insurance package. This medicinal product can be used in certain patients with obstructive hypertrophic cardiomyopathy (oHCM). This is a heart muscle disorder. If the Minister adopts our advice, aficamten will be included in the Medicines Reimbursement System (GVS) in a newly formed cluster with mavacamten. Only then will this medicinal product be reimbursed from the basic health insurance package. However, we do recommend additional conditions for reimbursement.
Current state of affairs: advice sent to the Minister
The National Health Care Institute has sent this advice to the Minister of VWS. The Minister makes the final decision on whether or not to reimburse the medicinal product from the basic health insurance package.
Aficamten is intended for people with a specific heart muscle disease
Aficamten is the active substance. The brand name is Myqorzo®. The medicinal product is a capsule that you swallow.
The medicinal product can be used in certain patients with obstructive hypertrophic cardiomyopathy (oHCM). Patients with oHCM have a thickened heart muscle, which prevents blood from being pumped effectively from the heart into the aorta, the body’s main artery. If standard treatment is not sufficiently effective, patients may be treated with aficamten.
The National Health Care Institute advice on the reimbursement of aficamten (Myqorzo®)
The National Health Care Institute advises the Minister of VWS to reimburse aficamten (Myqorzo®) from the basic health insurance package. The advice is to include the medicinal product in List 1A of the GVS, in a newly formed cluster with mavacamten. Certain additional conditions, the so-called List 2 conditions, apply for aficamten (Myqorzo®).
For more information on the GVS and Lists 1A, 1B and 2, see the page on ‘Reimbursement of outpatient medicines’.
Only for an insured person with symptomatic (NYHA class II- III) obstructive hypertrophic cardiomyopathy (oHCM), who
- either despite optimal beta-blocker or calcium antagonist use has persistent symptoms (NYHA ≥II)
- or has a proven contraindication or intolerance to beta-blockers or non-dihydropyridine calcium antagonists.
The prescription must be prescribed by a centre of expertise.
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicinal product, the personal expenses or whether you should pay a contribution, please ask your health insurance provider.
How did the advice come about?
The Minister of VWS asks the National Health Care Institute to make an assessment. The Minister makes the final decision whether or not to reimburse the medicinal product from the basic health insurance package.
Explanation about the reimbursement of medicinal products
Aficamten is an extramural medicinal product. ‘Extramural’ means medicines for home use that can be obtained at the pharmacy with a prescription from a physician. They are only reimbursed from the basic health insurance package if they are listed in the GVS.